In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the \u201coperation summary\u201d below, containing the information provided by the parties.<\/p>\n
This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.<\/p>\n
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented.<\/p>\n
Names of companies and individuals involved:<\/strong><\/p>\n Nature of the operation:<\/strong><\/p>\n Economic sector concerned:<\/strong><\/p>\n Deadline for interested third parties to submit their observations:<\/strong><\/p>\n NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n The Competition Council has received notification of an economic concentration project concerning the acquisition by the company \u201cHikma Mena FZE\u201d of the exclusive control of certain rights and assets held by the company \u201cTakeda Pharmaceutical International AG.\u201d<\/p>\n \u201cHikma Mena FZE\u201d is a limited liability company based in Dubai, a wholly-owned subsidiary of \u201cHikma Pharmaceuticals PLC,\u201d which manufactures specialized generic and branded pharmaceutical products across North America, the MENA region, North Africa, and Europe.<\/p>\n \u201cTakeda Pharmaceutical International AG\u201d is a Swiss public limited company, a subsidiary of \u201cTakeda Pharmaceutical Company Limited,\u201d engaged in research, development, and commercialization of innovative drugs in key therapeutic areas such as gastroenterology, oncology, rare diseases, and neuroscience.<\/p>\n <\/p>\n Done in Rabat, February 13, 2025<\/p>\n","protected":false},"excerpt":{"rendered":" In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the \u201coperation summary\u201d below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented. Names of companies and individuals involved: The acquirer: \u201cHikma Mena FZE\u201d; The target: Certain rights and assets held by the company \u201cTakeda Pharmaceutical International AG\u201d Nature of the operation: Exclusive control acquisition. Economic sector concerned: Pharmaceutical industry sector. Deadline for interested third parties to submit their observations: 10 days from the date of publication of this press release, i.e. February 26, 2025. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council has received notification of an economic concentration project concerning the acquisition by the company \u201cHikma Mena FZE\u201d of the exclusive control of certain rights and assets held by the company \u201cTakeda Pharmaceutical International AG.\u201d \u201cHikma Mena FZE\u201d is a limited liability company based in Dubai, a wholly-owned subsidiary of \u201cHikma Pharmaceuticals PLC,\u201d which manufactures specialized generic and branded pharmaceutical products across North America, the MENA region, North Africa, and Europe. \u201cTakeda Pharmaceutical International AG\u201d is a Swiss public limited company, a subsidiary of \u201cTakeda Pharmaceutical Company Limited,\u201d engaged in research, development, and commercialization of innovative drugs in key therapeutic areas such as gastroenterology, oncology, rare diseases, and neuroscience. Done in Rabat, February 13, 2025<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-40036","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"\n\n
\n
\n
\n